FindTrial
Sign In

Construction and validation of meibomian gland dysfunction grading model based on ocular surface comprehensive analyzer

Construction and validation of meibomian gland dysfunction grading model based on ocular surface comprehensive analyzer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105749
Enrollment
Unknown
Registered
2025-07-10
Start date
2025-08-01
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meibomian gland dysfunction

Interventions

MGD training group:None
MGD test group:None

Sponsors

Yangpu District Central Hospital, Shanghai (Yangpu Hospital,Tongji University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged >=18, <=80 years old, with clear meibomian gland images and complete data were included in the analysis.

Exclusion criteria

Exclusion criteria: The patients aged >=80 and <=18 years old who underwent comprehensive analysis of the ocular surface in our hospital had incomplete meibomian gland image data.

Design outcomes

Primary

MeasureTime frame
Meibomian gland loss rate;Eye redness analysis index;Tear film break-up time;—

Secondary

MeasureTime frame
Age;Sex;Ocular Surface Disease Index,OSDI;—

Countries

China

Contacts

Public ContactChen Yihui

Yangpu District Central Hospital, Shanghai (Yangpu Hospital,Tongji University)

cyh80h@163.com+86 193 0122 1798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026